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Abstract
Background: The selective MAO-B inhibitor selegiline has been evaluated in clinical trials as a
potential medication for the treatment of cocaine dependence. This study evaluated the safety of
and pharmacologic interactions between 7 days of transdermal selegiline dosed with patches
(Selegiline Transdermal System, STS) that deliver 6 mg/24 hours and 2.5 mg/kg of cocaine
administered over 4 hours.
Methods: Twelve nondependent cocaine-experienced subjects received deuterium-labeled
cocaine-d5 intravenously (IV) 0.5 mg/kg over 10 minutes followed by 2 mg/kg over 4 hours before
and after one week of transdermal selegiline 6 mg/24 hours. Plasma and urine were collected for
analysis of selegiline, cocaine, catecholamine and metabolite concentrations. Pharmacodynamic
measures were obtained.
Results: Selegiline did not change cocaine pharmacokinetic parameters. Selegiline administration
increased phenylethylamine (PEA) urinary excretion and decreased urinary MHPG-sulfate
concentration after cocaine when compared to cocaine alone. No serious adverse effects occurred
with the combination of selegiline and cocaine, and cocaine-induced physiological effects were
unchanged after selegiline. Only 1 peak subjective cocaine effects rating changed, and only a few
subjective ratings decreased across time after selegiline.
Conclusion: No pharmacological interaction occurred between selegiline and a substantial dose
of intravenous cocaine, suggesting the combination will be safe in pharmacotherapy trials. Selegiline
produced few changes in subjective response to the cocaine challenge perhaps because of some
psychoactive neurotransmitters changing in opposite directions.
Background
The acute administration of cocaine produces euphoria
and chronic administration produces hedonic dysregula-
tion, which are both believed to be mediated by dopamin-
ergic systems [1]. Chronic cocaine use-induced
dysregulation of the brain dopamine system may mediate
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BMC Clinical Pharmacology 2009, 9:13 http://www.biomedcentral.com/1472-6904/9/13cocaine reward, craving and relapse [2]. One approach to
treating this dysregulation has been the use of medica-
tions that increase dopamine activity. Selegiline, a rela-
tively selective monoamine oxidase (MAO)-B inhibitor at
lower doses has been investigated as a pharmacological
treatment for cocaine dependence.
Selegiline, approved for the treatment of Parkinson's Dis-
ease, inactivates MAO-B irreversibly and increases its sub-
strate dopamine in the synapse; reactivation requires at
least one to two weeks [3]. A placebo-controlled, double-
blind treatment trial using selegiline 10 mg per day orally
for eight weeks (a dose in the range selective for MAO-B)
suggested selegiline may be useful for the treatment of
cocaine dependence, based on decreases in quantitative
urine concentrations of the metabolite (benzoylecgonine)
and improved self- and investigator-rated global clinical
status (prepublication data, NIDA-MDD). However, a
later study using the selegiline transdermal system (STS)
was not as encouraging [4].
Transdermal selegiline is well tolerated, avoids the erratic
bioavailability from extrahepatic metabolism in the gut
[5] and extensive first pass metabolism [6], may decrease
the risk of hypertensive crisis ("cheese effect"), and may
decrease some of the side effects by decreasing generation
of selegiline's major metabolites, l-methamphetamine
and l-amphetamine [7].
Several studies have evaluated the safety of selegiline and
cocaine co-administration [8-11]. These studies all used a
single dose of 20 or 40 mg of intravenous (IV) cocaine for
each cocaine challenge session following daily dosing of
selegiline orally [8-10] or transdermally [11]. Our study
also evaluated the pharmacologic interactions between 7
days of patches delivering 6 mg/24 hours of selegiline
transdermally and cocaine. However, because persons
with cocaine dependence often use repeated larger doses
of cocaine during a period of use, we administered a larger
dose of cocaine (2.5 mg/kg) as an infusion over a longer
period of time (4 hours) to more closely simulate the
doses and duration of use reported by many patients. This
increased exposure to cocaine allowed assessment of
drug-drug interactions at drug levels likely to be encoun-
tered in clinical practice.
Because of the importance of dopamine to the rewarding
effects of drugs, concentrations of dopamine or its metab-
olites may help explain changes in the subjective effects of
cocaine given during selegiline administration. Homova-
nillic acid (HVA) is a major metabolite of dopamine
released in the brain, and although plasma concentrations
of this metabolite are influenced by other factors, it may
be a useful indicator of brain dopamine activity [12].
In addition to inhibiting the reuptake of dopamine,
cocaine is also a potent inhibitor of norepinephrine
reuptake. Measurement of urinary 3-methoxy-4-hydroxy-
phenylglycol (MHPG), the main excretory product of
norepinephrine, has been used as an index of the release
of brain norepinephrine. Because MHPG is conjugated to
MHPG-S in the central nervous system prior to excretion
[13] we chose to analyze for only the conjugated MHPG-
S in order to more specifically focus on brain norepine-
phrine activity.
Cocaine would be expected to increase brain norepine-
phrine turnover with a subsequent increase in urine levels
of MHPG-S. Acute doses of selegiline should also increase
synaptic norepinephrine and corresponding urinary
MHPH-S levels, unless significant MAO-A inhibition is
present, preventing the metabolism of norepinephrine to
MHPG. However, with sustained selegiline dosing, nore-
pinephrine depletion could occur and MHPG-S levels
could decline to baseline (or even below). Assessing the
effects of cocaine before and after treatment with sele-
giline could provide information about changes in
cocaine-induced norepinephrine regulation.
It is not clear how much, if any, MAO-A inhibition occurs
after treatment with 6 mg/24 hours of STS or what risk this
poses, particularly when other drugs or foods that increase
catecholamine activity are co-administered. Hypertensive
crises have been reported with MAO-A inhibitors and
sympathomimetic amines, such as phenylpropanolamine
[14]. The interactions between MAO-A inhibitors and
cocaine administered are largely unexplored. However,
cocaine during use of a MAO-A inhibitor did not produce
a hypertensive crisis in a preclinical study [15] and a case
report [16]. Since hypertensive crises do not occur in every
case, surrogate measures would be important. Therefore,
measurement of dopaminergic and noradrenergic tone
may be important in predicting toxic events. We measured
dopaminergic tone with the surrogate marker of plasma
HVA, the major brain metabolite of dopamine, and serum
levels of prolactin, a hormone whose secretion is inhib-
ited by dopamine. The surrogate for noradrenergic tone
was urine concentrations of MHPG-S. In order to assess
the degree of MAO-A and MAO-B inhibition, we assayed
concentrations of a substrate of MAO-B, phenylethyl-
amine (PEA) [17-19]. PEA would be expected to increase
with MAO-B inhibition, and concentrations of MHPG-S,
which is a metabolite of norepinephrine produced by
MAO-A primarily in the brain [20], would be expected to
decrease. Since MHPG-S is both an indicator of brain
norepinephrine activity and a metabolite of MAO-A, the
pattern of change (after initiation of selegiline administra-
tion and after cocaine administration) can help define
mechanistic interactions.Page 2 of 18
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cocaine and selegiline. We describe effects on dopamine,
norepinephrine, MAO-A, and MAO-B activity, and on
physiological and subjective effects of cocaine before and
after one week of transdermal selegiline.
Methods
Subjects
Subjects were recruited through newspaper advertise-
ments asking for volunteers to participate in studies of
cocaine effects. Subjects gave written informed consent
and were paid for participating. The protocol was
approved by the local Institutional Review Board and car-
ried out in compliance with the Declaration of Helsinki.
Inclusion criteria were as follows: age 21–45, ability to
give informed consent, previous experience with smoked
or intravenous cocaine and continuing cocaine use (rang-
ing from once a week to once in the last 6 months), good
health, and within 15% of ideal body weight. Subjects
were excluded for current dependence on any drug (except
caffeine or nicotine) as defined by the Diagnostic and Sta-
tistical Manual of Mental Disorders, Fourth Edition criteria,
pregnancy, or sensitivity to selegiline or related medica-
tions. Those interested in treatment or counseling were
given appropriate referral information at the conclusion
of the study.
Potential subjects were screened to eliminate those with
significant medical or psychiatric illnesses. Evaluation
included a comprehensive history and physical examina-
tion; an electrocardiogram; and laboratory tests, including
hepatitis C serology, EKG, pregnancy screen, and HIV test.
Study Medications
Deuterium labeled cocaine (cocaine-d5) for intravenous
infusions was synthesized and purified [21] from USP
grade cocaine hydrochloride (as outlined in IND
#51,280). The UCSF Investigational Pharmacy prepared
stock solutions of millipore filtered cocaine-d5 HCL in
preservative-free normal saline (NS) from crystalline
cocaine-d5 HCL. Cocaine-d5 was diluted for human
administration in sterile 0.9% sodium chloride. A sample
from each dose actually administered was assayed by gas
chromatography/mass spectrometry (GC/MS) to evaluate
concentration, stability, and quality control.
The STS (IND #42,302, 50,279, 46,944) 6 mg/24 hours
patch was applied to the upper torso daily for 10 days, just
below the fossa axillaris on the nondominant side, and
was kept on for 24 hours until application of the next
patch [22]. During both the inpatient and outpatient
phases, selegiline patches were applied at 9 AM. Patches
(lot #26E007D) were supplied by Somerset Pharmaceuti-
cals, Inc., Tampa, Florida.
Study Design
Subjects were admitted to the UCSF General Clinical
Research Center (GCRC). The following day (day 1), the
first cocaine infusion occurred; measures were collected
for the next 3 days. Transdermal selegiline administration
began on day 4 and the subject was discharged on day 5.
Selegiline administration was continued on an outpatient
basis. The subject was readmitted to the GCRC on day 10.
The second cocaine infusion took place the following day
(day 11) (2 hours after application of the selegiline patch)
and measures were collected for the next 3 days. At this
time the selegiline was discontinued and the subject was
discharged.
In this open-label, unblinded study, a 0.5 mg/kg intrave-
nous loading dose of cocaine-d5 HCl over 10 minutes was
followed by a slow 4 hour constant rate cocaine-d5 infu-
sion of 2.0 mg/kg(~175 mg for a 70 kg person). This pro-
duced a fairly stable plasma concentration over 4 hours.
When this method of cocaine administration is utilized, a
larger dose can be given over a longer period of time and
approximates frequently reported patterns of cocaine use
[23,24]. This method also allowed for close monitoring
and termination of the infusion if untoward psychiatric or
cardiovascular effects occurred.
The first infusion was performed 3 days prior to transder-
mal selegiline, and the second following one-week of
transdermal selegiline administered as one STS patch per
day. The order of cocaine infusions (i.e., following sele-
giline or prior to treatment) was fixed, as it may take sev-
eral weeks for MAO-B activity to return to normal after use
of the irreversible inhibitor selegiline [25].
Dietary Restrictions
Subjects were instructed to eat a diet low in monoamines
during the study. Breakfast and lunch were provided at the
GCRC. For meals outside the GCRC, a list of high
tyramine foods was provided with appropriate instruc-
tions. A daily food diary was collected and any lapses in
low monoamine guidelines were discussed with the sub-
jects.
Blood and Urine Collection
For both cocaine infusions (sessions 1 and 2), plasma
samples for cocaine and metabolites (~6 ml) were
obtained 5 minutes before and 10 minutes, 0.5, 1, 1.5, 2,
4, 4.25, 4.5, 5, 6, 8, 12, 21, 27, 33, and 45 hours after each
cocaine infusion. On day 4, a pre-dose plasma sample (~6
ml) was obtained 5 minutes before the selegiline patch
was applied at 9 AM. On outpatient days (days 5 and 9),
samples were taken 5 minutes prior to application of the
selegiline patch to determine steady state trough concen-
trations (Css) of selegiline and metabolites.Page 3 of 18
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(~6 ml) were obtained 5 minutes before application of
transdermal selegiline. In times referenced to the cocaine
infusion, samples for selegiline and metabolites (~6 ml)
were obtained pre and at 2, 4, 6, 12, 18, 24, 36, and 48
hours after the second cocaine infusion. Additional sam-
ples for selegiline and metabolites were taken 5 minutes
prior to the selegiline doses on the second and third day
after the cocaine challenge (days 12 and 13).
Samples (~10 ml) for HVA and prolactin were collected at
5 minutes before cocaine infusion and 0.5, 1, 1.5, 2, 3 and
4 hours after the beginning of the infusion. To obtain
accurate HVA measures, subjects remained recumbent for
30 minutes before and during the 4 hour infusion period.
If subjects needed to void during this period, they used a
hand-held urinal or a bedpan. Following collection, all
samples were frozen at -70°C until analyzed.
When subjects were in the GCRC, all urine was collected
and volumes recorded. Following each cocaine infusion,
urine was collected in fractions from 0 to 24, 24 to 48, and
48 to 72 hours (timed from the start of the infusion).
Samples were then frozen at -70°C until analyzed. Urine
samples were analyzed for selegiline and metabolites,
PEA, and MHPG-S. During the outpatient phase, a daily 9
AM (selegiline steady state) urine specimen was obtained
and analyzed for selegiline and metabolites. A qualitative
screen for drugs of abuse was obtained every other day for
the entire study period.
Pharmacodynamic Measures
Physiologic Measures
Heart rate, systolic and diastolic blood pressure were
measured using a cardiovascular monitor (Dinamap by
Critikon, Vital Signs Monitor 1846 SX). Rate pressure
product was calculated as the product of systolic blood
pressure and heart rate. Respiration rate was measured by
counting the number of inhalations per minute. These
vital signs were determined with the patient in a supine
position for at least 10 minutes.
Heart rate, blood pressure, respiration rate, skin and core
temperature were recorded at specific times during the
study. During infusions, measures were obtained pre-dose
and at 0.17, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.25, 4.5, 5,
6, 8, 12, 18, 24, 36, 48, and 72 hours after dosing. The
electrocardiogram was monitored continuously during
the infusion and for 4 hours after the termination of the
intravenous cocaine infusion. EKG tracings were recorded
at each data collection point.
Supervised administration of the transdermal selegiline
began on day 4 and continued through day 12. Since
orthostatic hypotension may occur with the administra-
tion of selegiline, orthostatic vital signs (i.e., blood pres-
sure, heart rate, respiration rate, in supine and standing
positions) were obtained prior to the transdermal sele-
giline and at 1 and 4 hours after application of the patch.
Subjective Measures
Verbal ratings of global intoxication and craving (on a
scale of 0 to 100) were obtained at the same time points
as the physiologic measures, with 0 representing no drug
effect and 100 representing the highest level of intoxica-
tion or craving.
Visual analog scales were used to rate the degree of drug
liking by moving an arrow along a 10 cm line marked at
opposite ends as 0 (not at all) and 100 (extreme) using a
hand-held computer (Tandy 102). Items rated on the vis-
ual analog scale included "good drug effect" and "bad
drug effect," and were obtained prior to cocaine infusion
and at 0.17, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.25, 4.5, 5,
6, and 8 hours after dosing.
The Profile of Mood States (POMS) [26] assessed mood
changes in Anger, Confusion, Fatigue, Tension, and Vigor
on a scale from 0 to 4, where 0 indicated "no effect" and
4 indicates "extremely strong". Ratings were obtained
prior to cocaine infusion and at 1, 3, and 6 hours after
dosing.
Determination of Metabolites in Plasma and Urine
Plasma concentrations of cocaine and benzoylecgonine
were measured in our laboratory using a method we
developed [27]. The method allows for simultaneous
determination of cocaine, benzoylecgonine, and deute-
rium-labeled analogs [cocaine-d5 and benzoylecgonine-
d5 (BE-d5)] by using combined gas chromatography-
mass spectrometry (GC-MS) [27]. Differently labeled sta-
ble isotope analogs were used as internal standards. The
calibration curves were from 5 to 2,000 ng/mL for
cocaine-d5 and 10 to 2,000 ng/mL for BE-d5. Lower limits
of quantitation (LLOQ) were 5 ng/ml (cocaine-d5) and
10 ng/ml (BE-d5) in plasma. Qualitative urine ben-
zoylecgonine was measured by Northwest Toxicology
Laboratory, Salt Lake City, Utah, using the Roche Diag-
nostics Online® immunoassay.
Plasma and urine selegiline and metabolites were ana-
lyzed by liquid chromatography-tandem mass spectrome-
try (LC/MS/MS) (Dr. Emil Lim, UCSF Drug Studies Unit,
San Francisco, CA). LLOQ was 0.025 ng/ml for selegiline
and 0.100 ng/ml for its metabolites, n-desmethysele-
giline, methamphetamine and amphetamine. Inter-day
precision, defined by coefficient of variation (CV), ranged
from 5.9 to 118% for selegiline, from 4.5 to 10.8% for n-
desmethylselegiline, from 3.9 to 6.5% for methampheta-
mine, and from 3.9 to 16.1% for amphetamine, with anPage 4 of 18
(page number not for citation purposes)
BMC Clinical Pharmacology 2009, 9:13 http://www.biomedcentral.com/1472-6904/9/13accuracy, defined by relative error (RE), of -5.4 to -6.5%
for selegiline and metabolites.
The analytical method and assay validation for determina-
tion of concentrations of PEA in urine was by LC/MS/MS.
LLOQ was 2.00 ng/ml for PEA. Interday CV ranged from
8.68 to 12.0%. RE ranged from -2.00 to +6.00%.
Serum prolactin was determined in duplicate by a direct
(CT) RIA method using kits purchased from ICN Biomed-
ical, Inc. (Costa Mesa, CA). The assay sensitivity was 0.1
ng/ml and the intra- and interassay CVs were 3.5 and
4.2%, respectively.
Plasma HVA was determined by HPLC. The HPLC
method was adapted from that described by Minegishi
and Ishizaki [28]. This method has a LLOQ of 2 ng/ml.
Concentrations of MHPG-S in urine were determined
using LC-MS/MS [29]. After discharge from the GCRC on
day 4 and during the outpatient period, subjects submit-
ted a 9 AM urine sample every day immediately before
application of the selegiline patch. As urinary creatinine
excretion is directly related to glomerular filtration and
renal blood flow, and urinary creatinine excretion is rela-
tively constant (~1 gm/day), it can be used to estimate
concentrations of a substance during a 24 hour urine col-
lection period. Using ratios of the concentrations of
MHPG-S to creatinine obtained from assays of these spot
urine samples, MGPG-S concentrations during the outpa-
tient period (when subjects would be unlikely to provide
accurate 24 hour urine collections) were compared to
those from urine samples on inpatient days.
Pharmacokinetic Analysis
The plasma concentration-time profiles for cocaine and
benzoylecgonine (BE) were analyzed by non-compart-
mental methods [30], utilizing the pharmacokinetic data
analysis program WinNonlin Pro, version 3.0 [31]. Data
from two subjects at two different time points were incon-
sistent with surrounding data, therefore, were considered
outliers and not included in the pharmacokinetic data
analysis.
The area under the plasma concentration-time curve was
calculated using the linear trapezoidal rule up to the max-
imum plasma concentration, and thereafter using the log-
arithmic trapezoidal rule to the last measurable plasma
concentration. The remaining area was extrapolated to
infinity by dividing the last appropriate plasma concentra-
tion by the terminal exponential rate constant.
Maximum plasma concentration (Cmax) and time of max-
imum plasma concentration (Tmax) were determined by
visual inspection of data. "Terminal" exponential half-life
[(t1/2)z] was calculated from log-linear regression of "ter-
minal" exponential phase data points. Cocaine clearance
(CL) and terminal exponential volume of distribution
(Vz) were calculated by conventional equations: CL =
[Dose/Area under the curve (AUC)0-∞] and Vz = CL/λz,
respectively, where λz ("terminal" exponential rate con-
stant) = ln2/(t1/2)z. BE renal clearance was calculated as:
amount in urine from 0 to 8 hours divided by AUC from
0–8 hours. Amount of BE in urine samples was calculated
by multiplying concentration by volume.
Statistical Analysis
For cocaine, descriptive statistics (mean, standard devia-
tion (SD), percent coefficient of variation (% CV),
median, minimum, and maximum) were calculated for
each parameter over each session. Because in most cases
one or both of the inherent assumptions of the ANOVA
were violated (normalcy of distributions and equivalence
of variances), the nonparametric Friedman test was uti-
lized.
For selegiline, the statistical analyses were performed
using the SAS Statistical Analysis System. All analyses
employed a one-factor repeated-measures analysis of var-
iance (ANOVA), with all parameters analyzed as their log-
arithmic (natural) transforms. If a day effect was found
between days 9, 11, 12, and 13, a Tukey multiple compar-
ison procedure was employed posthoc to compare the days
in pairs. A test for linear trend was included. All probabil-
ity estimates presented are based on the Type III sums of
squares.
The time courses of physiologic and subjective data were
analyzed by repeated measures analysis of variance
(ANOVA). Treatment conditions (Sessions 1 and 2) and
observation times (hours post-dose) were considered
within-subject factors. Change scores (post-dose minus
pre-dose values) were used in most analyses. Raw score
were used where indicated. After a significant F test, pair-
wise comparisons of treatment conditions were per-
formed using the least squares means analysis. Peak
effects within a session were determined for each subject
and each variable and analyzed using a one-factor
repeated measures ANOVA. Effects were considered statis-
tically significant at p = 0.05. Data were adjusted for
sphericity using the Huynh-Feldt adjustment factor.
Huynh-Feldt-corrected significance values are reported.
Results
Subjects
Eleven male and 1 female (mean age ± SD, 33 ± 7 years
[range, 22–44 years]) completed the study. The ethnicity
was predominately white with 9 Caucasians, one Asian,
one Hispanic, and one African-American. Typical use was
2 lines to 1 gm of cocaine per occasion. Four typicallyPage 5 of 18
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and three used both methods of administration (smoked
and intranasal route). Two subjects left prior to comple-
tion of the study, one as a result of an erectile dysfunction
that he believed had been caused by the study drug, and
the other for personal reasons.
Pharmacokinetic Results
The mean plasma concentration-time profiles of cocaine
and BE are shown in Figure 1 (one outlier is removed).
The BE AUC was approximately 5.9 times greater than that
of cocaine. No effect of selegiline on cocaine or BE plasma
pharmacokinetics was found following the removal of the
two outliers. Table 1 summarizes calculated cocaine phar-
macokinetic parameters and statistical results.
Mean plasma concentrations of selegiline and metabolites
rose slightly after cocaine with the largest increase occur-
ring 3 days after the cocaine infusion. However, the
trough plasma concentrations of only l-methampheta-
mine and l-amphetamine increased over time from days
9, 11, 12, and 13 (p for linear trend <0.001 and <0.01,
respectively). Figure 2 represents mean plasma concentra-
tions of selegiline and metabolites immediately before
and following the cocaine infusion.
Table 2 shows that the 24 hour urine collections (timed at
the start of the cocaine infusion, 2 hours after application
of transdermal selegiline) were not significantly different
for selegiline or its metabolites for the 0–24, and 24–48
hours collection periods. The concentration of selegiline
and each of its metabolites (desmethylselegiline, meth-
amphetamine, and amphetamine) in the 48–72 hour col-
lection period was less than that of the previous days.
However, it should be noted that the selegiline daily patch
was not applied the morning of the last day for the final
two hours. Thus, less would be expected.
Pharmacodynamic Measures
Physiologic Measures
Mean heart rate and rate pressure product after cocaine are
shown in Figure 3. Compared to baseline values, systolic
blood pressure, heart rate, and rate pressure product
increased significantly (p < 0.01). In contrast, skin tem-
perature decreased significantly (p < 0.01) during both
challenge sessions. Neither peak effects (Table 3) nor
physiological effects across time were affected by sele-
giline. Cocaine, either alone, or with selegiline did not
alter diastolic blood pressure, respiration rate, and core
temperature. Orthostatic blood pressure was within nor-
mal limits.
Subjective Measures
Mean verbal and visual analog subjective ratings across
time are shown in Figure 4 and POMS scales "anger" and
"tension" are in Figure 5. Compared to baseline, global
Table 1: Plasma Pharmacokinetic Parameters for Cocaine and Benzoylecgonine
Substance
(mean ± SD)
Cmax
(ng/ml)
Tmax
(hr)
AUC
(0-t)
(ng*h/ml)
λz
(1/hr)
(t1/2)z
(hr)
AUC
(0-∞)
(ng*h/ml)
AUCext
(%)
CL
(ml/min/kg)
Vz
(l/kg)
Cocaine
Pre 
Selegiline
(session 1)
721 ± 773 2.66 ± 1.74 2640 ± 55.6 0.453 ± 27.9 1.71 ± 0.81 2680 ± 1470 1.40 ± 1.03 18.3 ± 6.17 2.49 ± 0.88
Cocaine
With 
Selegiline
(session 2)
640 ± 332 2.27 ± 2.04 2360 ± 499 0.456 ± 0.09 1.57 ± 0.30 2400 ± 487 1.78 ± 1.87 18.0 ± 3.34 2.44 ± 0.64
Benzoyl-
ecgonine
Pre 
Selegiline
(session 1)
1045 ± 180 4.79 ± 0.50 13000 ± 3030 0.0928 ± 
0.023
8.63 ± 5.36 13600 ± 3820 3.45 ± 6.45
Benzoyl-
ecgonine
With 
Selegiline
(session 2)
957 ± 184 5.04 ± 0.65 12900 ± 3760 0.0971 ± 
0.024
7.52 ± 1.82 13200 ± 4180 2.21 ± 2.24
* Cmax = maximum plasma concentration; Tmax = time of Cmax; AUC(0-t) = area under the plasma concentration-time curve from 0 time to the time 
of the last measurable plasma concentration; AUC(0-∞) = area under the plasma concentration-time curve from 0 to infinity; AUCext (%) = percent 
of AUC(0-∞) determined by extrapolation; λz = "terminal" exponential rate constant; (t1/2)z = "terminal" exponential half-life; CL = clearance; Vz = 
"terminal" exponential volume of distribution; SD = standard deviation and %CV = percent coefficient of variation.Page 6 of 18
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Mean Plasma Cocaine (a) and Benzoylecgonine (b) Semi-logarithmic Plots for Cocaine Challenge Sessions 1 (before selegiline) and 2 (after selegiline)Figure 1
Mean Plasma Cocaine (a) and Benzoylecgonine (b) Semi-logarithmic Plots for Cocaine Challenge Sessions 1 
(before selegiline) and 2 (after selegiline).
a
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Mean Plasma Concentrations of Selegiline and Metabolites during Session 2Figure 2
Mean Plasma Concentrations of Selegiline and Metabolites during Session 2. Cocaine infusion began 2 hours after 
the application of the selegiline patch. (a) Black Circle = Selegiline, Open Circle = Desmethylselegiline. (b) Black Diamond = 
Methamphetamine, Open Diamond = Amphetamine. Error bars = SE.
BMC Clinical Pharmacology 2009, 9:13 http://www.biomedcentral.com/1472-6904/9/13intoxication, verbal ratings of craving, and "good drug
effect" increased in both cocaine challenge sessions. Only
the POMS "anger," "tension," and total score scales were
significantly different (lower) during the second session
(after selegiline). Verbal ratings of craving were also lower
in the second session between 1.5 and 4.5 hours after
cocaine (i.e., condition × time was significant).
Peak changes and peak times are shown in Table 3. No sig-
nificant differences in peak ratings were found between
sessions on the verbally reported or visual analog scales,
although cocaine craving showed a trend toward signifi-
cance with a lower rating in the second session (p < 0.06).
Peak rating for "anger" on the POMS was significantly
lower after selegiline (p < 0.03).
Metabolites and Modulators
Total amounts of PEA excreted in the 24-hour urine col-
lection are shown in Figure 6 and Table 4. PEA on day 4–
5 was higher than on day 3–4 (p < 0.05). After one week
of selegiline administration, cocaine produced signifi-
cantly greater mean PEA levels on each of the three days
following the cocaine challenge (on days 11–12, 12–13
and 13–14) compared to cocaine alone (day 3–4) (p <
0.01). Mean PEA concentration on day 12–13, the second
day after the second cocaine challenge, was significantly
Table 2: Selegiline and Metabolites Excreted in the 24 Hour Urines from 0–24, 24–48, and 48–72 hours After Cocaine (Mean ± SD, N = 
12)
Drug Assayed 0–24 hours
(day 11)
24–48 hours
(day 12)
Statistical p Value
0–24 vs. 24–48 hours
48–72 hours
(day 13)
Selegiline 0.109 ± 0.073 0.145 ± 0.138 0.34 0.063 ± 0.097
Desmethylselegiline 0.184 ± 0.128 0.188 ± 0.162 0.75 0.082 ± 0.086
l-Methamphetamine 6.26 ± 2.28 8.51 ± 5.69 0.20 4.83 ± 1.55
l-Amphetamine 2.34 ± 0.85 3.30 ± 2.34 0.18 2.15 ± 0.94
Infusion started on Day 11 at 11 AM, 2 hr after the 9 AM daily patch application.
No selegiline daily patch was applied at 9 AM on day 14.
Table 3: Physiologic and Subjective Measures – Summary of Peak Changes (Mean ± SD for 12 Subjects)
Session 1 Session 2
Measures Peak
Mean ± SD
Peak Time
(Hr Postdose)
Peak
Mean ± SD
Peak Time
(Hr Postdose)
Physiologic Measures
Systolic Blood Pressure (mmHg) 17 ± 8 2.2 ± 1.9 17 ± 9 1.9 ± 1.7
Diastolic Blood Pressure (mmHg) 10 ± 5 2.8 ± 2.4 12 ± 6 2 ± 2
Heart Rate (beats/min) 26 ± 10 0.8 ± 0.9 27 ± 12 0.9 ± 1.7
Rate Pressure Product (SBP*HR) 4224 ± 1638 1.4 ± 1.5 4437 ± 2333 0.9 ± 1.6
Respiration Rate (inhal/min) 3.8 ± 4.0 0.9 ± 1.3 3.8 ± 3.6 0.4 ± 0.3
Skin Temperature (°C) -5.4 ± 2.7 0.8 ± 0.4 -5 ± 3.2 1.0 ± 1.2
Core Temperature (°C) 0.7 ± 0.2 4.5 ± 1.6 0.7 ± 0.5 4.2 ± 1.9
Subjective Measures
Global Intoxication (0–100) 57 ± 27 0.7 ± 1 53 ± 23 0.6 ± 0.9
Cocaine Craving (0–100) 33 ± 25 1.1 ± 1.3 20 ± 21 0.6 ± 0.7
Good Drug Effect (0–100) 66 ± 23 0.9 ± 1.5 60 ± 21 1 ± 1.3
Bad Drug Effect(0–100) 46 ± 31 1.9 ± 2.3 55 ± 25 1.4 ± 1.9
POMS Scales
Tension (0–28) 7.5 ± 6.1 1 ± 0 4.8 ± 3.9 1 ± 0
Depression (0–64) 3 ± 6.5 3 ± 0 1.5 ± 2.4 3 ± 0
Anger (0–28) 2.8 ± 6.4 6 ± 0 -2.1 ± 5.7* 6 ± 0
Vigor (0–32) -3.6 ± 3.4 6 ± 0 -3.9 ± 6.1 6 ± 0
Confusion (0–20) 2.5 ± 2.8 6 ± 0 2.7 ± 4.7 3 ± 0
Fatigue (0–28) 5.9 ± 5.9 6 ± 0 2.8 ± 5.3 6 ± 0
* Significantly different from Session 1 (p < 0.03).
Session 1: First cocaine infusion, performed on day 1, before selegiline administration.
Session 2: Second cocaine infusion, performed on day 11, following one week of selegiline administration by STS patch (6 mg/24 hours). Infusion 
began 2 hours after application of the selegiline daily patch.Page 9 of 18
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Mean Heart Rate Readings (a) and Rate Pressure Product (b)Figure 3
Mean Heart Rate Readings (a) and Rate Pressure Product (b). Open Square = Session 1, Black Circle = Session 2. 
Error bars = SE.
BMC Clinical Pharmacology 2009, 9:13 http://www.biomedcentral.com/1472-6904/9/13higher when compared to selegiline alone on day 4–5 (p
= 0.01). No significant difference was found between PEA
concentrations on days 11–12, 12–13, and 13–14.
Concentrations of serum prolactin (ng/ml) during the
first cocaine infusion session (before selegiline) and the
second session (after 5 days of selegiline; Figure 7) were
not significantly different between sessions. Serum prolac-
tin levels numerically decreased after cocaine in both chal-
lenge sessions, but because of the high variability of the
data, the change within each session was not significant.
Plasma HVA concentrations after cocaine challenge
Mean Subjective Measures: Verbal and Visual Analog Scale RatingsFigure 4
Mean Subjective Measures: Verbal and Visual Analog Scale Ratings. (a) Intoxication, (b) Craving, (c) Good Drug 
effect, (d) Bad Drug Effect. Open Square = Session 1, Black Circle = Session 2. Error bars = SE.Page 11 of 18
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Mean Subjective Measures: Profile of Mood States (POMS) MeasuresFigure 5
Mean Subjective Measures: Profile of Mood States (POMS) Measures. Open Square = Session 1, Black Circle = Ses-
sion 2. Error bars = SE.
BMC Clinical Pharmacology 2009, 9:13 http://www.biomedcentral.com/1472-6904/9/13showed a trend (p < 0.1) toward a significant decrease at
the second session following subchronic selegiline (Figure
7).
Urine MHPG-S/creatinine concentration ratios increased
significantly (p < 0.05) the second day after the first
cocaine challenge and marginally (p < 0.1) the first and
third day afterwards compared to the day before cocaine
challenge. Selegiline began on day 4, and urinary MHPG
S concentrations based on MHPG-S to creatinine ratios
(Figure 8) did not return to baseline until day 10, the day
prior to the second cocaine challenge session. However,
after the second cocaine challenge the urinary MGPG-S
concentrations continued to decline (though not signifi-
cantly) rather than increasing. The MHPG-S concentration
and MHPG-S/creatinine ratios in the three days after the
second cocaine challenge were significantly lower (p <
0.01) compared to the three days after the first cocaine
challenge.
Adverse Events
One subject reported erectile dysfunction after starting sel-
egiline and dropped out of the study. One subject experi-
enced anxiety and one reported insomnia after beginning
the patch. One subject vomited during each cocaine infu-
sion (Session 1 and Session 2).
Discussion
Pharmacokinetic Measures
Plasma cocaine pharmacokinetics were unaffected by sel-
egiline administration. After removal of the two outliers,
urinary BE recovery was also unaffected. This is consistent
with the similar plasma-time concentration curves found
by Houtsmuller and colleagues [11] with a 40 mg cocaine
challenge before and after 6 mg/24 hours of transdermal
selegiline for 10 days. This absence of change in cocaine
pharmacokinetics after 5 days of selegiline administration
is important, because treatment trials of cocaine depend-
ence often use urinary toxicology screens based on the
presence of benzoylecgonine or quantitative benzoylecgo-
nine concentrations as outcome measures.
Trough levels of selegiline and metabolites were similar to
those reported previously after subchronic dosing [11].
Physiologic and Subjective Effects
Physiological changes in response to cocaine were not sig-
nificantly different between sessions. Houtsmuller et al.
[11] have reported significant differences in heart rate and
systolic blood pressure in response to a cocaine challenge
after transdermal selegiline, while others [9] have not.
In our study, higher ratings of anger and tension across
time were seen after cocaine alone than after cocaine and
selegiline administration. Selegiline decreased craving for
more cocaine between 1.5 and 4.5 hours following the
cocaine infusion, a time when many users re-administer
cocaine. However, cocaine craving was unchanged at the
time of peak cocaine effects. The order of cocaine chal-
lenges was not randomized; that is, selegiline plus cocaine
always followed cocaine alone. Because of the irreversible
inhibition of selegiline requiring weeks for recovery, a bal-
anced order design was not practical. Therefore, theoreti-
cally, this decrease in the second session could have been
due to habituation or other factors. However, we and oth-
ers [32-34] have not observed a change in subjective
effects of cocaine with repeated within-subject dosing in
previous studies. Except for a small decrease in POMS-
rated anger, there were no other changes in subjective rat-
ings and physiologic measures between cocaine chal-
lenges.
The lack of significant differences in the rewarding or
stimulating effects of cocaine after transdermal selegiline
Table 4: Total Amount of PEA and MHPG (mg) Excreted in the 24 Hour Urine Collection Prior to and After Application of the 
Selegiline Patch
Measure Day 3–4
After Cocaine 
Preselegiline
Day 4–5
0–24 hr Postselegiline
Day 11–12
Selegiline Phase
1st Day After 
Cocaine•
Day 12–13
Selegiline Phase
2nd Day After 
Cocaine†
DAY 13–14
Selegiline Phase
3rd Day After 
Cocaine‡
PEA 0.003 ± 0.004 0.132 ± 0.095* 0.260 ± 0.171**** 0.229 ± 0.145**** 0.159 ± 0.104**
MHPG-S 1.44 ± 0.43 1.43 ± 0.40 1.09 ± 0.23** 1.07 ± 0.40** 1.01 ± 0.33**
Infusion started on Day 11 at 11 AM, on day 11, 2 hours after 9 AM patch application.
• Selegiline patch applied @ 9 AM Day 12;
† Selegiline patch applied @ 9 AM Day 13;
‡ No selegiline patch was applied at 9 AM on Day 14.
* Changed from Day 3–4, p < 0.05
** Greater than Day 3–4, p < 0.01
*** Greater than Day 3–4, p < 0.001
**** Greater than Day 3–4, p < 0.0001Page 13 of 18
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contrast with reports of others [10,9,11] that found
decreases in such measures as "high," "stimulated," "good
effects," and "liking." These studies administered a
smaller amount of cocaine (20 mg to 40 mg) in a single
bolus over one minute or less. Our study administered a
greater total dose of cocaine over a longer period of time,
which we hoped would more closely simulate frequently
reported larger doses of cocaine use. Under these condi-
tions, selegiline did not alter the intoxicating or pleasura-
ble effects of cocaine.
Bartzokis and colleagues [10] found that selegiline
reversed the reduction in activity in the amygdala
observed on PET imaging produced by a 40 mg dose of
cocaine and decreased hippocampal activity both before
and after cocaine challenge. Amygdala activity is postu-
lated to be related to the rewarding effects of the drug and
selegiline's reversal of cocaine's effect on activity of the
amygdala may interfere with cocaine's reinforcing proper-
ties [10]. Another stimulant-like drug, methylenedi-
oxymethamphetamine (MDMA), has been found to
decrease activity in the amygdala related to some subjec-
tive effects [35]. Hippocampal activity is thought to be
related to memory and craving (reviewed in [10]). Since
reward and craving may have different mechanisms, it is
interesting to note that the larger dose selegiline used in
our study still decreased later craving but did not decrease
the pleasurable effects of cocaine, as found in other stud-
ies. However, the decrease in craving may still be very
important clinically and might lead to a decrease in use in
motivated patients.
Orthostatic vital signs and cardiovascular monitoring,
obtained during the selegiline maintenance phase,
revealed no adverse cardiovascular effects from this daily
selegiline dose. No significant adverse effects resulted
from the administration of cocaine following selegiline
administration. Selegiline used as a treatment for cocaine
dependence does not appear to significantly increase risk
of adverse consequences from a lapse to cocaine use dur-
ing treatment, even at the higher doses commonly
reported by cocaine users.
Catecholamine Modulators and Metabolites
PEA
PEA has methamphetamine discriminative-stimulus and
reinforcing-stimulus effects [36,37], which suggests the
potential to modulate the response to stimulant drugs
[38]. It is metabolized by MAO-B [17,19,18]. MAO-B
inhibitors increase PEA brain concentrations [37] there-
fore, PEA is also an indicator of MAO-B activity. Selegiline
also appears to increase the reinforcing stimulus effects of
PEA [37]. Consistent with MAO-B inhibition, selegiline
marginally increased urinary PEA excretion compared to
cocaine alone in our study. Cocaine challenge following
transdermal selegiline significantly increased urinary PEA
compared to cocaine alone, as also found by Houtsmuller
and colleagues [11]. Cocaine has been reported to poten-
tiate the amphetamine-induced increase of PEA in the rat
brain [39]. As selegiline is metabolized into l-metham-
phetamine and l-amphetamine, this synergistic effect of
cocaine and selegiline on PEA increase could be expected
by this mechanism also, as well as by MAO inhibition.
Serum Prolactin and Plasma HVA
Our failure to find any differences in prolactin response
has been previously reported [11]. Changes in plasma and
serum concentrations of hormones and neurotransmitter
metabolites are limited in their ability to reflect CNS
changes. CNS changes may have been obscured by periph-
eral factors. Plasma HVA concentrations during cocaine
challenge showed a trend towards significance for a
decrease following subchronic selegiline. This would sug-
gest that subchronic dosing of selegiline produces a more
general dampening, if anything, of dopamine activity,
rather than enhanced dopamine activity as predicted by
the augmentation by selegiline of cocaine-induced
increase in nucleus accumbens dopamine found in
rodents [40]. Again, central-peripheral and regional brain
differences could account for this discrepancy. Our HVA
data, though not quite significant, are consistent with
Newton and colleagues' [9] hypothesis that selegiline
might decrease the rewarding effects of cocaine by reduc-
ing the increase in dopamine release following cocaine
administration, although we did not see a rise in basal
dopamine availability as they suggest. Another explana-
tion of our marginally decreased HVA concentration is
that MAO inhibition led to smaller amounts of HVA pro-
duction from dopamine, regardless of dopamine changes.
Mean PEA Excreted in 24 Hour Urine CollectionFigure 6
Mean PEA Excreted in 24 Hour Urine Collection. Sel-
egiline started on Day 4. Error bars = SE.Page 14 of 18
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Mean Serum Prolactin and Plasma HVA Concentrations During Cocaine Challenge Session 1 and 2Figure 7
Mean Serum Prolactin and Plasma HVA Concentrations During Cocaine Challenge Session 1 and 2. Open 
Square = Session 1, Black Circle = Session 2. Error bars = SE.
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selves decrease density of some types of dopamine recep-
tors and other monoaminergic receptors [41] and could
therefore decrease dopamine-mediated effects even with-
out change in dopamine concentrations. PEA potentiates
actions of dopamine and norepinephrine, and Boulton et
al. [42] suggest a co-relationship between PEA and
dopamine may exist. A complex relationship between
PEA, neurotransmitter release and elimination, and
monoamine receptor density might explain the decrease
in craving found by us and others [11] and the decrease in
the rewarding effects from a smaller dose of cocaine found
by others [10,9,11].
MHPG-S
Our 4-hour cocaine infusion increased urinary MHPG-S
levels for at least four days. Elevated urinary MHPG-S is
thought to represent elevations in brain norepinephrine
turnover, presumably due to increased release of nore-
pinephrine into synapses with subsequent diffusion of
metabolized norepinephrine out of the synapse and even-
tually into the systemic circulation. Therefore, a relatively
brief exposure to cocaine elevated CNS norepinephrine
turnover for at least three days. A direct effect of cocaine
may not be the only explanation for the sustained eleva-
tions in MHPG-S excretion because the acute pharmacok-
inetic and dynamic effects of cocaine decline rapidly, with
a half life of about 1 hour [32]. Therefore, it is more likely
that cocaine (or a metabolite) induced longer lasting
changes in norepinephrine regulation. Cocaine can
induce long-term changes in brain neurotransmitter regu-
lation through multiple mechanisms.
Selegiline blocks biotransformation of norepinephrine to
MHPG and should decrease urinary MHPG-S levels if sig-
nificant MAO-A activity is present. Cocaine alone
Mean MHPG-S per Gram of Creatinine Excreted in Urine for Daily Pre-Patch Administration Urine SamplesFigure 8
Mean MHPG-S per Gram of Creatinine Excreted in Urine for Daily Pre-Patch Administration Urine Samples. 
Error bars = SE.Page 16 of 18
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administration, MHPG-S levels gradually returned to
baseline values. Selegiline blocked the cocaine-induced
MHPG-S increase at the second challenge session. The sig-
nificantly lower urinary MHPG-S concentrations after
cocaine challenge following selegiline suggests that at this
dose it may have an attenuating effect on MHPG-S pro-
duction, an indication of MAO-A inhibition. This is con-
sistent with findings in rats that transdermal selegiline
also produces MAO-A inhibition in the brain even though
inhibition in the gut is not clinically significant [43].
Conclusion
Administration of a larger dose of cocaine over a longer
period of time than in previously reported studies was
well tolerated. This dose and duration more closely mim-
ics a binge pattern of cocaine abuse and may yield more
clinically relevant data on expected drug interactions with
cocaine. With this cocaine dosing strategy, transdermal
selegiline produced no significant cardiovascular adverse
effects. Elevations in PEA concentrations suggest that this
dose of transdermal selegiline inhibited MAO-B. The
decrease in MHPG-S levels in response to cocaine chal-
lenge suggest that some MAO-A inhibition may have also
taken place. The sustained increase in MHPG-S for days
after the initial cocaine administration suggest mecha-
nisms other than a direct effect of cocaine. Indicators of
dopamine activity, plasma HVA and serum prolactin, sug-
gested no increase in cocaine-induced dopamine activity
following transdermal selegiline, and possibly even a
small decrease in dopaminergic activity, although central-
peripheral differences or variations in regional brain activ-
ity may have prevented detection of important changes.
Transdermal selegiline decreased ratings of cocaine-
induced anger and tension and later craving ratings but
did not decrease the rewarding effects of this relatively
larger dose of and longer administration of cocaine, con-
sistent with different mechanisms for cocaine craving and
reward. The largely negative effects of selegiline on
response to cocaine in this laboratory study may explain
the results of a study of clinical evaluation of treatment
utility [4] suggesting that selegiline is not helpful as a
treatment agent, despite some initial signs of clinical suc-
cess. Testing response to potential therapeutic agents
using cocaine doses closer to those more typically used by
dependent persons is likely to better generalize to
addicted populations. It is possible that a subpopulation
of dependent persons, such as those with lighter use or
those within a particular range of motivation to abstain,
might benefit from this treatment or that yet undiscovered
subtyping methods, such as genetic studies, might identify
a more responsive group.
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